Key facts
- This page summarizes Andrea F. Wainer's Form 4 filing for ABBOTT LABORATORIES (ABT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Feb 2025, 18:56.
Andrea F. Wainer - 25 Feb 2025 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- EXECUTIVE VICE PRESIDENT
- Issuer ticker
- ABT
- Reported as of
- 25 Feb 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2025, 18:56:35 UTC
- Prior SEC filing
- 19 Feb 2025
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Andrea F. Wainer by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Andrea F. Wainer filed Form 4 for ABBOTT LABORATORIES (ABT) on 27 Feb 2025.
Change
- Previous filing in this sequence was filed on 19 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
transaction
Common shares without par value
Award
- Transaction value
- $0
- Shares
- +12,278
- Change %
- +17%
- Price
- $0.000000
- Shares after
- 82,643
- Date
- 25 Feb 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABT
transaction
Derivative
Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +45,730
- Change %
- Price
- $0.000000
- Shares after
- 45,730
- Date
- 25 Feb 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 45,730
- Exercise price
- $135.42
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
Footnote F2
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,243 on February 25, 2026, 15,243 on February 25, 2027, and 15,244 on February 25, 2028.